


In the Claims:See
Remarks >

Please Cancel claims 13-15 and 17-18

Please Amend Claims 1-12 and 16 as follows.

1. (Currently Amended) A compound of formula (I)



wherein:

R is represents halogen or C₁₋₄ alkyl;R₁ is represents hydrogen or C₁₋₄ alkyl;R₂ is represents hydrogen , C₁₋₄ alkyl or R₂ together with R₃ represents C₃₋₇ cycloalkyl;R₃ is represents hydrogen, C₁₋₄ alkyl, C₃₋₇ cycloalkyl or C₃₋₆ alkenyl; or R₁ and R₃ together with nitrogen and carbon atom to which they are attached respectively represent a 5 to 6 membered heterocyclic group;R₄ is represents trifluoromethyl, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethoxy or halogen;R₅ is hydrogen and R₆ is NR₇R₈ or R₅ is NR₈R₉ and R₆ is hydrogen;R₇ is represents hydrogen or C₁₋₄ alkyl or R₇ and R₈ together with nitrogen to which they are attached are a saturated 5 to 7 membered heterocyclic group containing oxygen;R₈ is represents hydrogen, phenyl, C₃₋₇ cycloalkyl, (CH₂)_pC(O)NR₁₀R₁₁, a saturated 5 to 7 membered heterocyclic group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally substituted by C₁₋₄ alkyl, S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl, a 5 membered heteroaryl group containing 1 to 3 heteroatoms selected from oxygen, sulphur and nitrogen and optionally

substituted by C₁₋₄ alkyl S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl or R₈ represents a 6 membered heteroaryl group containing 1 to 3 nitrogen atoms and optionally substituted by C₁₋₄ alkyl, S(O)₂C₁₋₄ alkyl or C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl; or R₈ is a C₁₋₆ alkyl group optionally substituted by one or two groups selected from fluorine, phenyl(optionally substituted by C₁₋₄ alkyl, C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl or halogen), =O, C₃₋₇ cycloalkyl, hydroxy, amino, dimethylamino, aminocarbonyl, C₁₋₄ alkoxy or trifluoromethyl;

R₉ is hydrogen, C₁₋₄ alkyl or R₉ and R₈ together with nitrogen to which they are attached are a 5 to 7 membered heterocyclic group optionally containing another heteroatom selected from oxygen, sulphur and nitrogen and optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O, S(O)₂C₁₋₄ alkyl, C(O)C₃₋₇ cycloalkyl C(O)C₃₋₇ cycloalkyl or C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl;

R₁₀ and R₁₁ are independently hydrogen or C₁₋₄ alkyl group;

X is represents a nitrogen atom and Y is CH or X represents CH and Y is nitrogen;

m is zero or an integer from 1 to 3;

n is an integer from 1 to 3;

p is zero, 1 or 2;

or a and pharmaceutically acceptable salt or solvate salts and solvates thereof.

2. (Currently Amended) A compound as claimed in claim 1 wherein R₆ is NR₇R₈ and R₅ is hydrogen, Y is nitrogen and X is CH ~~or wherein R₆ is hydrogen and R₅ is NR₇R₈, Y is CH and X is nitrogen.~~

3. (Currently Amended) A compound as claimed in claim 1 ~~or claim 2~~ wherein R is a halogen (e.g. fluorine) and/or a C₁₋₄ alkyl (e.g. methyl) group and m is zero or an integer from 1 to 2.

4. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 3~~ wherein R₁ is a methyl group.
5. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 4~~ wherein R₂ is a hydrogen atom or a methyl group.
6. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 5~~ wherein R₃ is a hydrogen atom or a methyl group.
7. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 6~~ wherein R₄ is a trifluoromethyl group and/or halogen (i.e. chlorine) and n is 2.
8. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 7~~ wherein R₅ is hydrogen, NH(C₃₋₇ cycloalkyl), NH(C₁₋₄ alkylC₃₋₇ cycloalkyl), 1-piperazinyl(optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O, S(O)₂C₁₋₄ alkyl, C(O)C₃₋₇ cycloalkyl C(O)C₃₋₇ cycloalkyl or C(O)C₁₋₄ alkyl C(O)C₁₋₄ alkyl); piperidyl (optionally substituted by one or two groups selected from C₁₋₄ alkyl, =O,) or morpholino.
9. (Currently Amended) A compound as claimed in claim 1 ~~any claims from 1 to 8~~ wherein R₆ is hydrogen, N(C₁₋₆alkyl)₂, NH(C₁₋₆alkyl), NH(CH₂)_pC(O)NR₁₀R₁₁ wherein p is 1 or 2 and R₉ and R₁₀ are independently hydrogen or methyl, NH(C₁₋₆ alkyltrifluoromethyl), NH(C₁₋₆alkylC₁₋₄alkoxy), NH(C₁₋₆alkylfluorine), N(C₁₋₆ alkyl)(C₁₋₆ alkylfluorine), NH(C₁₋₆ alkylphenyl), NH(C₃₋₇cycloalkyl), NH(piperidyl), NH (C₁₋₆ alkyl aminocarbonyl), NH(C₁₋₆ alkyl-1.3 dioxolan-yl) or morpholino.
10. (Currently Amended) A compound as claimed in ~~any claims from 1 to 9~~ wherein R₆ is NR₇R₈ and R₅ is hydrogen, Y is nitrogen and X is CH or wherein R₆ is hydrogen and R₅ is NR₈R₉, Y is CH and X is nitrogen;

R₇ is hydrogen or methyl;

R₈ is methyl, ethyl, dimethylpropyl, cyclopropyl, cyclobutyl, CH₂C(O)NH₂, piperidinyl, 1-methyl-piperidinyl, methyl substituted by a group selected from phenyl, cyclopropyl, 4-acetyl-piperazino, fluorine, methoxy, trifluoromethyl and 1,3 dioxolan-yl;

R₉ is hydrogen or methyl;

R₉ and R₈ together with nitrogen to which they are attached is 1-piperazinyl, acetyl-1-piperazinyl, morpholino;

R₇ and R₈ together with nitrogen to which they are attached is morpholino;

R is independently fluorine or methyl;

R₄ is trifluoromethyl and/or chlorine;

m is 1 or 2; and

n is 2.

11. A compound as claimed in claim 1 any claims from 1 to 10 selected from :

4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride;

4-(S)-Dimethylamino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride;

4-(S)-(2-Fluoroethyl)-amino-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethyl-phenyl)-ethyl]-methylamide hydrochloride; and


4-(S)-(2-Fluoro-ethylamino)-2-(R)-(4-fluoro-2-methyl-phenyl)-piperidine-1-carboxylic acid (3,5-bis-trifluoromethyl-benzyl)-methylamide hydrochloride.

✓12-14. (Canceled).

15. (Currently Amended) A pharmaceutical composition comprising a compound as claimed in claim 1 ~~any claims from 1 to 11~~ in a mixture with one or more pharmaceutically acceptable carriers or excipients.

16. (Canceled.)

17. (Currently Amended) A process for the preparation of a compound as claimed claim 1 comprising in any claims from 1 to 11 by reductive N-alkylation of a compound of formula (II), wherein R₁₂ is =O and R₁₃ is hydrogen or R₁₂ is hydrogen and R₁₃ is =O



with an amine derivative (III) or ~~salt~~ a salt thereof in the presence of a suitable metal reducing agent,

followed where necessary or desired by one or more of the following steps:

- i) ~~removing removal of~~ any protecting group;
- ii) ~~isolating isolation of~~ the compound as a salt or a solvate thereof;
- iii) ~~separating separation of a the~~ compound of formula (I) or derivative thereof into the enantiomers thereof.

Please add new claims 18-24.

18. (New) A compound as claimed in claim 1, wherein R₆ is hydrogen and R₅ is NR₈R₉, Y is CH and X is nitrogen

19. (New) A method for the treatment of a condition mediated by a tachykinin in a mammal comprising administering an effective amount of a compound as claimed in claim 1.

20. (New) The method as claimed in claim 19, wherein said tachykinin is substance P.

21. (New) The method as claimed in claim 19, wherein said mammal is man.

22. (New) A method for the treatment of a CNS disorder in a man comprising administering an effective amount of a compound as claimed in claim 1.

23. (New) The method according to claim 22, wherein said CNS disorder is selected from depressive states and anxiety.

24. (New) A method for the treatment of emesis in a mammal comprising administering an effective amount of a compound as claimed in claim 1.